CRTKVA11-N04 / CorreGene - LARVOL DELTA

Phase 1 trial of a KRAS G12V/HLA-A*11:01–restricted TCR-engineered T-cell therapy in advanced solid tumors. (ASCO 2026) - P1 | "Pts received lymphodepletion with cyclophosphamide and fludarabine, followed by a single infusion of TCR-T cells at either 5×10⁹ (DL1) or 1×10¹⁰ (DL2) cells, with adjunctive interleukin-2... This KRAS G12V/HLA-A*11:01–restricted TCR-T therapy demonstrated a favorable safety profile and encouraging preliminary antitumor activity in advanced solid tumors. Notably, a high response rate was observed in heavily pretreated pancreatic cancer patients, supporting further clinical development of this novel cellular therapy."

IO biomarker • Metastases • P1 data • Colorectal Cancer • Endometrial Cancer • Neutropenia • Oncology • Pancreatic Cancer • Solid Tumor • Thrombocytopenia • CD8 • IL2 • KRAS